Liu, Hengrui http://orcid.org/0000-0002-5214-1572
Forouhar, Farhad
Seibt, Tobias
Saneto, Russell
Wigby, Kristen
Friedman, Jennifer
Xia, Xin
Shchepinov, Mikhail S.
Ramesh, Sanath Kumar
Conrad, Marcus
Stockwell, Brent R. http://orcid.org/0000-0002-3532-3868
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5 P30 CA013696-39S3, P01CA87497, R35CA209896)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R61NS109407)
Article History
Received: 9 April 2021
Accepted: 1 October 2021
First Online: 20 December 2021
Competing interests
: B.R.S. is an inventor on patents and patent applications related to GPX4 and ferroptosis, and is a consultant to and cofounder of Inzen Therapeutics and Nevrox Limited, and is a member of the Scientific Advisory Board of Weatherwax Biotechnologies Corporation, and a consultant to Akin Gump Strauss Hauer & Feld LLP. M.C. is an inventor of ferroptosis-related patents and cofounder and shareholder of ROSCUE Therapeutics GmbH. J.F. participates in clinical trials with Biogen (Angelman’s syndrome) and J.F.’s spouse is Founder and Principal of Friedman Bioventure, which holds a variety of publicly traded and private biotechnology interests. M.S.S. is the Chief Scientific Officer of Retrotrope, Inc.